xamoterol has been researched along with metoprolol in 12 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (metoprolol) | Trials (metoprolol) | Recent Studies (post-2010) (metoprolol) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 5,821 | 1,743 | 1,304 |
| Protein | Taxonomy | xamoterol (IC50) | metoprolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.573 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.176 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bashir, Y; Camm, AJ; Farrell, TG; Griffith, MJ; Paul, VE; Sneddon, JF; Ward, DE | 1 |
| Camm, AJ; Griffith, M; Paul, V; Ward, DE | 1 |
| Erhardt, L; Melcher, A; Persson, H; Rythe'n-Alder, E | 1 |
| Erhardt, L; Eriksson, SV; Persson, H | 1 |
| Carson, PE | 1 |
| Andréasson, K; Erhardt, L; Eriksson, SV; Hall, C; Hjemdahl, P; Kahan, T; Persson, H; Tidgren, B | 1 |
| Böhm, M; Dabew, E; Engelhardt, S; Lohse, MJ; Lorenz, K; Maack, C; Schäfers, HJ; Vlaskin, L | 1 |
1 review(s) available for xamoterol and metoprolol
| Article | Year |
|---|---|
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failure; Heart Rate; Hemodynamics; Humans; Imidazoles; Male; Metoprolol; Middle Aged; Propanolamines; Propranolol; Quality of Life; Stroke Volume; Time Factors; Vasodilator Agents; Xamoterol | 1999 |
5 trial(s) available for xamoterol and metoprolol
| Article | Year |
|---|---|
A prospective study of the efficacy and safety of adjuvant metoprolol and xamoterol in combination with amiodarone for resistant ventricular tachycardia associated with impaired left ventricular function.
Topics: Adult; Aged; Amiodarone; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Metoprolol; Middle Aged; Prospective Studies; Stroke Volume; Tachycardia, Ventricular; Ventricular Function, Left; Xamoterol | 1992 |
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone.
Topics: Adrenergic beta-Agonists; Adult; Aged; Amiodarone; Drug Resistance; Drug Therapy, Combination; Electric Stimulation; Exercise Test; Female; Heart Ventricles; Humans; Male; Metoprolol; Middle Aged; Propanolamines; Random Allocation; Tachycardia; Xamoterol | 1989 |
Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Exercise Test; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Prospective Studies; Xamoterol | 1995 |
Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol. Echocardiographic results from the Metoprolol and Xam
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiac Output, Low; Double-Blind Method; Echocardiography; Echocardiography, Doppler; Female; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Ventricular Function, Left; Xamoterol | 1996 |
Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Chi-Square Distribution; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography, Doppler; Epinephrine; Female; Follow-Up Studies; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Neuropeptide Y; Norepinephrine; Probability; Proportional Hazards Models; Prospective Studies; Survival Rate; Treatment Outcome; Xamoterol | 2002 |
6 other study(ies) available for xamoterol and metoprolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atrial Function; Heart Atria; Heart Failure; Heart Rate; Humans; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Transgenic; Middle Aged; Myocardial Contraction; Organ Specificity; Propanolamines; Propranolol; Receptors, Adrenergic, beta-1; Species Specificity; Xamoterol | 2003 |